LOXL2 and breast cancer: Weidenfeld K et al. demonstrated that dormant tumour cells (DTCs) overexpressing LOXL2 acquire a cancer stem cell (CSC)-like phenotype, promoting the growth and proliferation of recurrent breast cancer cells 58.